What is the initial treatment for adenocarcinoma (a type of cancer that originates in glandular tissue) of the stomach?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Treatment for Gastric Adenocarcinoma

The initial treatment for gastric adenocarcinoma should be determined by disease stage, with surgical resection as the only potentially curative option for localized disease, and perioperative chemotherapy with ECF (epirubicin, cisplatin, and 5-FU) recommended for stage IB or higher disease. 1

Diagnostic Workup and Staging

Before initiating treatment, proper staging is essential to determine the appropriate therapeutic approach:

  • Complete physical examination, blood counts, liver and renal function tests 1
  • Contrast-enhanced CT scan of thorax and abdomen (± pelvis) for initial staging 1
  • Endoscopy with biopsy for histological confirmation 1
  • Endoscopic ultrasound (EUS) for determining T and N stages, especially helpful in early disease 1
  • Laparoscopy ± peritoneal washings recommended for all stage IB-III stomach cancers to detect occult metastatic disease 1
  • PET imaging may improve staging through increased detection of involved lymph nodes/metastatic disease 1

Treatment Algorithm Based on Disease Stage

Early Gastric Cancer (T1a)

  • Endoscopic mucosal resection may be considered in experienced centers 1
  • This approach is suitable for well-differentiated tumors ≤2 cm confined to the mucosa 1

Localized Disease (T1b-T3)

  • Surgical resection with adequate margins (typically 4 cm from gross tumor) 1
  • Options include distal gastrectomy, subtotal gastrectomy, or total gastrectomy depending on tumor location 1
  • Gastric resection should include regional lymphatics with D2 lymphadenectomy (perigastric lymph nodes and those along named vessels of the celiac axis) 1
  • At least 15-16 lymph nodes should be examined for adequate staging 1, 2

Locally Advanced Disease (≥Stage IB)

  • Perioperative chemotherapy with ECF (epirubicin, cisplatin, and 5-FU) is recommended (category 1) 1
  • Alternative approach: Surgery followed by adjuvant chemoradiotherapy with fluoropyrimidine (5-FU or capecitabine) 1
  • The European MAGIC trial demonstrated improved progression-free and overall survival with perioperative chemotherapy compared to surgery alone 1

T4 Tumors

  • Require en bloc resection of involved structures 1
  • May benefit from neoadjuvant chemotherapy to downstage the tumor before surgical intervention 1

Metastatic Disease (Stage IV)

  • Palliative chemotherapy is recommended 1
  • Standard regimens include:
    • DCF (docetaxel, cisplatin, and 5-FU) (category 1) 1, 3
    • ECF (epirubicin, cisplatin, and 5-FU) (category 1) 1
    • For HER2-positive tumors, trastuzumab in combination with chemotherapy 1

Special Considerations

  • Multi-disciplinary treatment planning is mandatory, involving surgeons, medical and radiation oncologists, gastroenterologists, radiologists, and pathologists 1
  • Patients should be referred to higher-volume centers with adequate support to manage potential complications 2
  • Laparoscopic resections should be performed to the same standards as open resections by surgeons experienced in both advanced laparoscopic surgery and gastric cancer management 2
  • For gastric adenocarcinoma, docetaxel in combination with cisplatin and fluorouracil is FDA-approved for patients who have not received prior chemotherapy for advanced disease 3

Common Pitfalls to Avoid

  • Underestimating the extent of disease: Diagnostic laparoscopy is crucial to detect occult peritoneal metastases not visible on CT 1
  • Inadequate lymphadenectomy: D2 lymphadenectomy is preferred over D1 for curative-intent resection 2
  • Insufficient lymph node assessment: At least 16 lymph nodes should be examined for proper staging 2
  • Performing palliative gastric resection in asymptomatic patients with metastatic disease: Surgery should be considered only for palliation of symptoms in the metastatic setting 2

Recent advances in molecular profiling have led to more personalized treatment approaches, with HER2 status assessment now standard for all gastric adenocarcinomas to determine eligibility for targeted therapy 1, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of gastric adenocarcinoma: A rapidly evolving landscape.

European journal of cancer (Oxford, England : 1990), 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.